망막정맥폐쇄와 당뇨망막병증에서 황반부종 치료를 위한 유리체내 베바시주맙 주입술의 효과

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the long-term results of intravitreal bevacizumab injection for macular edema (ME) due to retinal vein obstruction (RVO) and diabetic retinopathy (DR). Methods: The objects of study were patients with decreased visual acuity due to ME with RVO and DR for whom intravitreal injections of 1.25 mg (0.05 ml) bevacizumab were repeated three times with an interval of six weeks and who were available for a follow-up period of more than 12 months. The patients underwent additional bevacizumab injections if ME increased as assessed by optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline and follow-up visits. Results: There were 16 patients with RVO and 18 patients with DR. In the RVO group, the mean length of follow-up was 12.4±1.1 months, the mean baseline BCVA was 0.75±0.32 and the final BCVA was 0.42±0.25, a difference that was statistically significant (p＜0.05). The mean CMT at baseline was 588.5±301.0 μm and this decreased to a mean of 191.8±112.0 μm at the end of the follow-up period (p＜0.05). In the DR group, the mean length of follow-up was 15.4±3.2 months, the mean baseline BCVA was 0.63±0.33 and the final BCVA was 0.61±0.37, a difference that was not statistically significant (p＞0.05). The mean CMT at baseline was 462.0±195.0 μm and decreased to a mean of 282.2±177.3 μm at the end of the follow-up period (p＜0.05). Conclusions: In RVO and DR, three injections of intravitreal bevacizumab with an interval of six weeks and additional injections as indicated were effective in reducing ME and showed especially good results in improvement of visual acuity for ME due to RVO.

참고문헌 (Reference)

1 황중혁, "당뇨황반부종의 치료에서 유리체절제술의 효과" 대한안과학회 44 (44): 1079-1084, 2003

2 Brooks HL Jr, "Vitreous levels of vascular endothelial growth factor and stromalderived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone" 122 : 1801-1807, 2004

3 Funatsu H, "Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema" 113 : 294-301, 2006

4 Ferrara N, "Vascular endothelial growth factor: molecular and biological aspects" 237 : 130-, 1999

5 Aiello LP, "Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor" 46 : 1473-1480, 1997

6 Pe’er J, "Vascular endothelial growth factor upregulation in human central retinal vein occlusion" 105 : 412-416, 1998

7 Vinores SA, "Upregulation of vascularendothelial growth factor in ischemic and nonischemic human and experimental retinal disease" 12 : 99-109, 1997

8 Fraser-Bell S, "Update on treatments for diabetic macular edema" 19 : 185-189, 2008

9 Wu L, "Twelve-month safety of intravitreal injections of bevacizumab: results of the Pan-American Collaborative Retina Study Group (PACORES)" 246 : 81-87, 2008

10 Itakura H, "Triamcinolone acetonide suppresses interleukin-1 beta mediated increase in vascular endothelial growth factor expression in cultured rat Muller cells" 244 : 226-231, 2006

11 Pournaras JA, "Treatment of central retinal vein occlusion-related macular edema with intravitreal bevacizumab (avastin): preliminary results" 225 : 397-400, 2008

12 Badalà F, "The treatment of branch retinal vein occlusion with bevacizumab" 19 : 234-238, 2008

13 Michel RG, "The natural course of retinal branch vein obstruction" 78 : 166-177, 1974

14 Byeon SH, "Short-term results of intravitreal bevacizumab for macular edema with retinal vein obstruction and diabetic macular edema" 23 : 3887-394, 2007

15 Meleth AD, "Serum inflammatory markers in diabetic retinopathy" 46 : 4295-4301, 2005

16 Takahashi MK, "Role of the vitreous and macular edema in branch retinal vein occlusion" 28 : 294-299, 1997

17 Orth DH, "Retinal branch vein occlusion" 22 : 357-376, 1978

18 Ryan SJ, "Retina. in" Macular edema, 3rd ed. v. 2. chap. 57" The C.V. Mosby Co 2001

19 Ozdemir H, "Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema" 140 : 251-255, 2005

20 Early Treatment Diabetic Retinopathy Study Group, "Photocoagulation for diabetic macular edema. ETDRS report no. 1" 103 : 1796-1806, 1985

21 Noma H, "Pathogenesis of macular edema with branched retinal vein obstruction and intraocular levels of vascular endothelial growth factor and interleukin-6" 140 : 256-261, 2005

22 Arevalo JF, "Pan- American Collaborative Retina Study Group (PACORES). Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up" 114 : 743-750, 2007

23 Rosenfeld PJ, "Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration" 36 : 331-335, 2005

24 Höh AE, "OCT-guided reinjection of 2.5 mg bevacizumab for treating macular edema due to retinal vein occlusion" 105 : 1121-1126, 2008

25 Zhang Y, "Natural history and histology in a rat model of laser-induced photothrombotic retinal vein occlusion" 33 : 365-376, 2008

26 Gutman FA, "Macular edema secondary to occlu sion of the retinal vein" 28 : 462-470, 1984

27 Finkelstein D, "Laser treatment of macular edema resulting from branch vein occlusion" 9 : 23-28, 1994

28 Finkelstein D, "Ischemic macular edema: recognition and favorable natural history in branch vein occlusion" 110 : 1427-1434, 1992

29 Kim KS, "Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion" 86 : 925-927, 2008

30 Antcliff RJ, "Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study" 108 : 765-772, 2001

31 Martidis A, "Intravitreal triamcinolone for refractory diabetic macular edema" 109 : 920-927, 2002

32 Park CH, "Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion" 136 : 419-425, 2003

33 Greenberg PB, "Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion" 86 : 247-248, 2002

34 Tolentino MJ, "Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate" 103 : 1820-1828, 1996

35 Jonas JB, "Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy" 84 : 1064-1067, 2000

36 Jonas JB, "Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy" 131 : 468-471, 2001

37 Gündüz K, "Intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion" 22 : 1168-1171, 2008

38 Costa RA, "Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study" 27 : 141-149, 2007

39 Haritoglou C, "Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema" 26 : 999-1005, 2006

40 Rabena MD, "Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion" 27 : 419-425, 2007

41 Ozkiriş A, "Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema" 25 : 2008

42 Jonas JB, "Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema" 132 : 425-427, 2001

43 Aiello LP, "Hypoxic regulation of vascular endothelial growth factor in retinal cells" 113 : 1538-1544, 1995

44 Early Treatment Diabetic Retinopathy Study Group, "Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no.19" 113 : 1144-1155, 1995

45 The Central Vein Occlusion Study Group, "Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report" 102 : 1425-1433, 1995

46 Shimura M, "Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema" 145 : 854-861, 2008

47 Stahl A, "Bevacizumab in retinal vein occlusion-results of a prospective case series" 245 : 1429-1436, 2007

48 Neubauer AS, "Bevacizumab and retinal ischemia" 114 : 2096-, 2007

49 The Branch Vein Occlusion Study Group, "Argon laser photocoagulation for macular edema in branch vein occlusion" 98 : 271-282, 1984

50 Duff IF, "Anticoagulant therapy in occlusive vascular disease of retina" 46 : 601-617, 1951

51 Wu L, "American Collaborative Retina Study Group (PACORES). Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up" 28 : 212-219, 2008